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Inorganic arsenic (As) is ubiquitous in the 
environment, and individuals can be exposed 
to As from mining and smelting metal ores, 
pesticide manufacturing and application, 
and wood preservatives (Mandal and Suzuki 
2002). For the general public, ingestion of 
As-contaminated food and drinking water is 
the primary route of exposure (Mandal and 
Suzuki 2002). Currently, populations in 
Southeast Asia are among the most likely to be 
exposed to As due to the use of contaminated 
groundwater for drinking water, with tens of 
millions of people exposed to As in Bangladesh 
(Alam et al. 2002). Other countries including 
Mexico, Chile, Argentina, and the United 
States also have regions using groundwater for 
consumption that is contaminated with natu-
rally occurring As (Amini et al. 2008).
Chronic exposure to As is associated with 
increased risk of cancer and neurological, cardio-
vascular, respiratory, hepatic, and hematological 
disease (Vahter 2008). Epidemiological studies 
show that chronic exposure to As is associated 
with an increased risk of mortality from cardio-
vascular disease, infectious disease, and cancer 
(Sohel et al. 2009). Inorganic As is classified as 
a known human carcinogen (Bates et al. 1992) 
but it is not a potent mutagen. When As is 
administered alone it does not produce tumors 
in traditional animal models, but it can act as a 
carcinogen in animal models using fetal expo-
sure paradigms because As crosses the placenta 
(National Research Council 2001; Tokar et al. 
2011b). Transplacental studies in mice show 
that the offspring of dams who were given 0, 
42.5, and 85 ppm As via drinking water from 
gestational day 8 to 18 (last two-thirds of preg-
nancy) had a dose-dependent increase in liver, 
lung, ovary, and adrenal tumors when they 
reached adulthood (Waalkes et al. 2003, 2004). 
Furthermore, mice that received As expo-
sure in utero and throughout their life course 
 developed more frequent and aggressive tumors 
at much lower doses compared with mice who 
only received As exposure during the  gestational 
period (Tokar et al. 2011a).
These studies generated considerable 
interest in the potential for As to alter epi-
genetic programming in the fetus (Barker 
1992; Edwards and Myers 2007; Jirtle and 
Skinner 2007; Waterland and Michels 2007; 
Wu et al. 2004). Because DNA methylation 
patterns are established during embryogenesis 
and play an important role in gene transcrip-
tion, chromosomal stability, X-chromosome 
inactivation, tissue differentiation, and sup-
pression of repetitive DNA sequences, per-
manently altering fetal DNA methylation 
is a potential mechanism linking in utero 
exposures to chronic diseases in adulthood 
(Geiman and Muegge 2010; Sasaki and 
Matsui 2008). Moreover, animal models show 
that DNA methylation in fetal tissues can be 
altered by arsenic, maternal diet, bisphenol A, 
vinclozolin, and ethanol, and that the changes 
in DNA methylation are associated with a 
shift in the distribution of adult phenotypes 
(Dolinoy et al. 2006, 2007; Kaminen-Ahola 
et al. 2010; Waterland and Jirtle 2003; Xie 
et al. 2007).
Epidemiological studies in adults have 
observed that chronic arsenic exposure from 
drinking contaminated water is associated 
with increased methylation in DNA extracted 
from whole blood leukocytes (Chanda et al. 
2006; Majumdar et al. 2010; Pilsner et al. 
2007; Smeester et al. 2011). Yet little is known 
about how in utero exposures to As affects 
DNA methylation, or how As exposure affects 
methylation in healthy individuals. Therefore, 
we examined the association between drink-
ing-water As exposure and DNA methylation 
in paired maternal and umbilical cord leuko-
cytes using data collected from a prospective 
birth cohort in Bangladesh. The outcome of 
this analysis was the percentage of methylated 
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Background: Arsenic is an epigenetic toxicant and could influence fetal developmental 
 programming.
oBjectives: We evaluated the association between arsenic exposure and DNA methylation in 
maternal and umbilical cord leukocytes.
Methods: Drinking-water and urine samples were collected when women were at ≤ 28 weeks ges-
tation; the samples were analyzed for arsenic using inductively coupled plasma mass spectrometry. 
DNA methylation at CpG sites in p16 (n = 7) and p53 (n = 4), and in LINE-1 and Alu repetitive 
elements (3 CpG sites in each), was quantified using pyrosequencing in 113 pairs of maternal and 
umbilical blood samples. We used general linear models to evaluate the relationship between DNA 
methylation and tertiles of arsenic exposure.
results: Mean (± SD) drinking-water arsenic concentration was 14.8 ± 36.2 μg/L (range: 
< 1–230 μg/L). Methylation in LINE-1 increased by 1.36% [95% confidence interval (CI): 0.52, 
2.21%] and 1.08% (95% CI: 0.07, 2.10%) in umbilical cord and maternal leukocytes, respectively, 
in association with the highest versus lowest tertile of total urinary arsenic per gram creatinine. 
Arsenic exposure was also associated with higher methylation of some of the tested CpG sites in the 
promoter region of p16 in umbilical cord and maternal leukocytes. No associations were observed 
for Alu or p53 methylation.
conclusions: Exposure to higher levels of arsenic was positively associated with DNA methyla-
tion in LINE-1 repeated elements, and to a lesser degree at CpG sites within the promoter region of 
the tumor suppressor gene p16. Associations were observed in both maternal and fetal leukocytes. 
Future research is needed to confirm these results and determine if these small increases in methyla-
tion are associated with any health effects.
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cytosines (%mC) in the promoter regions of 
two tumor suppressor genes (p16 and p53) 
that act as checkpoints in the cell cycle, and in 
two repetitive elements [LINE-1 (long inter-
spersed nucleotide elements) and Alu (short 
interspersed elements)]. These repeated ele-
ments account for approximately 25% of the 
human genome and are heavily methylated, 
which is presumed to silence their transcription 
(Kochanek et al. 1993; Rangwala et al. 2009).
Methods
Subject selection and recruitment. In this 
analysis we used samples collected from a pro-
spective birth cohort recruited in Sirajdikhan 
Upazila of Bangladesh. The objective of this 
cohort was to observe the effects of chronic 
low-level As exposure on reproductive out-
comes. Groundwater testing by the British 
Geological Survey indicated that this area 
was moderately As contaminated (British 
Geological Survey 2001). Additionally, Dhaka 
Community Hospital (DCH) directs arse-
nic awareness programs in this area that pro-
vide tubewell testing and encourage people to 
drink only from tubewells that comply with 
the Bangladesh drinking-water standard of 
< 50 μg As/L.
DCH-trained health care workers who live 
in the villages serviced by the clinic identified 
pregnant women and invited them to join the 
study. Women were eligible to participate if 
they were ≥ 18 years of age, had an ultrasound-
confirmed singleton pregnancy of < 28 weeks 
gestation, used a tubewell that supplied ground-
water as their primary drinking-water source, 
planned to live at their current residence for 
the duration of the pregnancy and continue 
prenatal health care with DCH, and agreed 
to deliver at DCH or at home with a DCH-
trained midwife. An additional criterion for this 
analysis was that the participant must have used 
the same tubewell for ≥ 6 months before enroll-
ment. Study staff administered questionnaires 
that collected sociodemographic information, 
medical histories, and other covariates at the 
time of enrollment. As an incentive, all par-
ticipants were provided with free prenatal care 
from DCH and prenatal vitamins that were 
replenished during monthly checkups in the 
participant’s home. Informed consent was pro-
vided by all participants before enrollment. This 
study was approved by the Human Research 
Committees at the Harvard School of Public 
Health, DCH, and Oregon State University.
Water As. At the time of enrollment, a 
water sample was collected from the tube-
well that each participant identified as their 
primary source of drinking water. Briefly, 
water samples were collected in 50-mL poly-
propylene tubes (BD Falcon; BD Bioscience, 
Bedford, MA, USA) and preserved with 
reagent grade HNO3 (Merck, Germany) 
to a pH < 2. Samples were kept at room 
temperature before analysis by inductively 
coupled plasma–mass spectrometry follow-
ing U.S. Environmental Protection Agency 
method 200.8 (Environmental Laboratory 
Services, North Syracuse, NY, USA). The 
average (± SD) percent recovery of As from 
PlasmaCAL multi-element QC standard #1 
solution (SCP Science, Canada) was 102% 
± 7%. Of the 114 samples included in this 
analysis, 51 (44.7%) had an As concentration 
below the 1-μg As/L limit of detection (LOD).
Urinary As. At the time of enrollment, 
participants provided a spot urine sample dur-
ing their clinical visit. Briefly, urine was frozen 
at –20°C and shipped on dry ice to Taipei 
Medical University for analysis following 
protocols described by Hsueh et al. (1998). 
Arsenite (AsIII), arsenate (AsV), monomethyl-
arsonic acid (MMA), and dimethylarsinic acid 
(DMA) were quantified by high- performance 
liquid chromatography (Waters 501; Waters 
Associates, Milford, MA, USA) and hydride-
generated atomic absorption spectrometry 
(Flow Injection Analysis System 400AA 
100; Perkin-Elmer, Waltham, MA, USA). 
Total urinary arsenic (TUA) was calculated 
by adding AsIII + AsV + MMA + DMA. This 
approach eliminates interference from arseno-
betanine and arsenocholine, which are organic 
As species found in fish and shellfish.
The average LOD was 0.05 μg/L. The 
average (± SD) percent recovery of spiked 
samples was 98.9% ± 6.5%, 100% ± 6.5%, 
99.9% ± 6.4%, and 100.1% ± 6.5% for AsIII, 
AsV, MMA, and DMA, respectively. The 
average percent difference of replicate sam-
ples composed of standard As solutions was 
–1.0% ± 3.5%, 0% ± 3.9%, –0.3% ± 3.4%, 
and –1.3% ± 3.4% for AsIII, AsV, MMA, 
and DMA. Urinary creatinine was measured 
using the kinetic Jaffe method with a Hitachi 
7170S autoanalyzer (Hitachi, Tokyo, Japan). 
Creatinine-adjusted urinary arsenic concentra-
tions were derived by dividing total urinary 
arsenic (micrograms per liter) by creatinine 
(grams per liter).
DNA methylation. Whole blood was col-
lected in an EDTA-coated vacutainer (BD 
Scientific, Franklin Lakes, NJ, USA) from 
the mother at the time of enrollment and at 
28 weeks gestation via venipucture. Blood was 
collected from the umbilical cord shortly after 
birth via a syringe or by milking the cord. 
DNA was extracted from 4 mL whole blood 
using Puregene DNA isolation solutions fol-
lowing manufacturer’s instructions (Qiagen/
Gentra Systems, Minneapolis, MN, USA). 
DNA was stored at 4°C.
DNA methylation analyses were per-
formed on bisulfite-treated DNA using a 
quantitative assay based on PCR (polymerase 
chain reaction)–pyrosequencing. The detailed 
method, location of the gene promoters, 
amplified regions, and CpG sites that were 
evaluated have been published previously 
(Kile et al. 2010). Briefly, DNA was treated 
using the EZ-96 DNA Methylation-Gold™ 
Kit (Zymo Research, Orange, CA, USA). 
Then DNA was amplified using bisulfite-
PCR. The PCR product underwent pyrose-
quencing using the PyroMark™ Q96 MD 
Pyrosequencing System (Pyrosequencing, 
Inc., Westborough, MA) using sequencing 
primers described by Pavanello et al. (2009) 
and are provided in Supplemental Material, 
Tables 1 and 2 (http://dx.doi.org/10.1289/
ehp.1104173). The percentage of methylated 
and unmethylated cytosines was quantified 
for 3 CpG sites in Alu, three CpG sites in 
LINE-1, seven CpG sites in p16, and four 
CpG sites in p53. Methylation was expressed 
as the %mC over the sum of methylated and 
unmethylated cytosines in the CpG sites 
tested. Each marker was pyrosequenced in two 
replicates and the results averaged.
Non-CpG cytosine residues were used 
to verify bisulfite conversion. The success of 
pyrosequencing in the umbilical cord sam-
ples was 100%, 97%, 99%, and 91% for Alu, 
LINE-1, p16, and p53, respectively. The suc-
cess of pyrosequencing in the maternal samples 
from blood drawn at the time of enrollment 
was 76%, 76%, 75%, and 61% for Alu, 
LINE-1, p16, and p53. To increase the num-
ber of maternal samples, DNA methylation 
results for blood collected at 28 weeks gesta-
tional age was substituted for the failed sam-
ples. Subsequently, maternal samples include 
blood drawn at the time of enrollment and at 
28 weeks gestational age.
Statistical analysis. Drinking-water As con-
centrations and total urinary arsenic adjusted 
for creatinine were categorized into tertiles. 
The %mC was averaged across the three CpG 
sites evaluated in LINE-1 and in Alu, and the 
average values were used to represent LINE-1 
and Alu methylation (respectively) in all statis-
tical analysis. In contrast, the seven CpG sites 
evaluated in p16 and the four CpG sites in p53 
were each evaluated separately. It is unknown 
whether all CpG sites within promoter regions 
are equally susceptible to environmental 
exposures such as As. Therefore, we chose to 
evaluate the association between arsenic and 
individual CpG site in the promoter regions 
of p16 and p53 instead of using an average 
methylation within each promoter region. 
Improving our understanding of the sensitivity 
of CpG sites in promoter regions has implica-
tions for some commercially available methyla-
tion arrays that select only one or more CpG 
sites within the promoter region of genes.
We calculated descriptive statistics for all 
DNA methylation outcomes, As exposures, 
and selected subject characteristics. Spearman 
correlation coefficients were used to evalu-
ate the relationship between water As and 
creatinine-adjusted total urinary arsenic 
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(TUA/g). General linear regression models 
were used to estimate the association between 
DNA methylation (%mC) at each site and 
As exposure via drinking-water As (micro-
grams per liter) or TUA (micrograms per gram 
creatinine), with each exposure categorized 
by tertiles. Additional covariates were evalu-
ated in the models including body mass index 
(BMI; continuous), maternal age (years), 
infant sex, delivery method (vaginal/cesar-
ean), gestational age (weeks), and prematu-
rity (< 37 weeks/≥ 37 weeks). Only maternal 
BMI and prematurity were significantly asso-
ciated with methylation and were included 
in the final adjusted models. Additionally, we 
evaluated the association between total uri-
nary arsenic (micrograms per liter) and DNA 
methylation in models that included creatinine 
as an independent variable [see Supplemental 
Material, Table 3 (http://dx.doi.org/10.1289/
ehp.1104173)]. All analyses were performed 
in SAS version 9.1 (SAS Institute Inc., 
Cary, NC, USA).
Results
In this analysis we used data from 114 paired 
maternal and umbilical cord blood samples. 
These samples were selected because the moth-
ers and their infants were healthy, there were 
complete covariate data, and DNA was avail-
able from both mother and infant. Of these 
participants, one individual had a drinking-
water As level that was much higher (734 μg 
As/L) than the next highest value (230 μg 
As/L). This sample was an outlier, and con-
sequently this mother and her infant were 
excluded from the analysis, resulting in a final 
sample size of 113 mother–infant pairs.
All participants used groundwater as their 
primary source of drinking water for at least 
6 months before enrollment. A general descrip-
tion of the population and DNA methylation 
outcomes are presented in Table 1. Ultrasounds 
were used to confirm pregnancy and estimate 
gestational age, which was, on average (± SD), 
13.3 ± 4.8 weeks (range, 4.8–25 weeks) at 
the time of enrollment. On average, moth-
ers were 23.5 years old with a BMI of 21.0 
(range, 13.4–29.0), although 20.2% of the 
mothers were underweight (BMI < 18.5). 
The average birth weight was 2,786 g (range, 
1,740–3,520 g), and 11.5% of infants were 
premature (< 37 weeks). The vast majority of 
the births were vaginal and took place at home 
in the presence of a midwife (94.5%), with the 
remainder delivered by cesarean section in the 
hospital. There were also fewer male infants 
than expected (44.3%). All women were given 
prenatal vitamins and encouraged to take them 
daily, but two women reported that they did 
not take the vitamins because of nausea or a 
preference not to take medication.
Overall, arsenic exposures were modestly 
elevated in this population (Table 2), which 
is consistent with expectations for residents of 
villages participating in arsenic remediation 
programs. At enrollment, drinking-water As 
concentrations ranged from < 1 to 230 μg/L 
with a median concentration of 1.2 μg/L. 
Maternal total urinary arsenic concentrations 
adjusted for creatinine (TUA/g) were strongly 
correlated with maternal drinking-water As 
(ρ = 0.32, p = 0.0006). Arsenic exposures were 
categorized into tertiles for statistical analy-
sis. For drinking-water As, the low (< 1 μg/L), 
medium (1–1.9 μg/L), and high tertiles 
(1.9–230 μg/L) had average As of 0.5, 1.4, and 
42.3 μg/L, respectively. For TUA/g, the low 
(< 0.35 μg/g), medium (0.35–0.65 μg/g), and 
high (0.66–21.87 μg/g) tertiles had average As 
of 0.22, 0.50, and 2.35 μg/g, respectively. The 
distribution of As in this population resulted in 
a very small concentration difference between 
the low and medium tertiles of As exposure.
LINE-1 and Alu. We used general lin-
ear regression models to estimate associations 
between LINE-1 and Alu DNA methylation 
and As exposure. For LINE-1, higher levels 
of As exposure were associated with increased 
methylation. In umbilical cord leukocytes 
(Figure 1A), LINE-1 methylation increased in 
the medium tertile and in the high tertile com-
pared with the lowest tertile of drinking water 
As (Table 3). When As exposure was expressed 
using TUA/g, LINE-1 methylation in umbili-
cal cord leukocytes (Figure 1A) also increased 
with As exposure although the relationship was 
significant only in the highest tertile of TUA/g 
Table 1. General description of the population providing maternal and umbilical cord blood (n = 113).
Variable n Mean ± SD Minimum Maximum
Cesarean section (yes) 6 (5.3%)
Premature (< 37 weeks) 13 (11.5%)
Infant sex (male) 50 (44.3%)
Prenatal vitamins (no) 2 (1.8%)
Maternal age (years) 113 23.5 ± 4.2 18 38
Maternal BMI 113 21.0 ± 3.1 13.4 29.0
Birth weight (g) 113 2,786 ± 335 1,740 3,520
Gestational age at enrollment (weeks) 113 13.3 ± 4.8 4.7 25.9
Maternal drinking-water As (μg/L) 113 14.8 ± 36.2 < 1 230
Total urinary As (μg/L) 113 25.3 ± 260.3 0.05 260.3
Total urinary As (μg/g creatinine) 113 1.01 ± 2.6 0.004 21.87
Urinary creatinine (mg/dL) 113 35.6 ± 31.7 3.4 172.8
Cord blood leukocytes (%mC)
LINE-1 109 80.6 ± 1.9 76.2 85.3
Alu 113 25.0 ± 0.8 76.0 85.1
p16 position 1 112 2.4 ± 1.4 0.87 9.17
p16 position 2 112 2.8 ± 1.3 1.08 6.98
p16 position 3 112 1.4 ± 0.8 0 6.09
p16 position 4 112 2.1 ± 1.0 0.85 5.82
p16 position 5 112 2.1 ± 0.9 1.06 7.66
p16 position 6 112 1.3 ± 0.8 0 5.03
p16 position 7 112 2.4 ± 1.1 0.88 6.60
p53 position 1 103 2.5 ± 0.9 0 7.91
p53 position 2 103 7.5 ± 2.8 2.95 24.13
p53 position 3 103 2.5 ± 1.3 0 13.22
p53 position 4 103 3.7 ± 1.5 0 12.58
Maternal blood leukocytes (%mC)
LINE-1 101 80.2 ± 2.1 76.0 85.1
Alu 103 25.2 ± 0.7 25.5 27.5
p16 position 1 101 2.6 ± 1.5 0.60 10.87
p16 position 2 101 3.1 ± 1.7 1.05 12.51
p16 position 3 101 1.4 ± 0.6 0 3.21
p16 position 4 101 2.2 ± 1.0 0.73 5.45
p16 position 5 101 2.2 ± 0.7 1.23 4.54
p16 position 6 101 1.2 ± 0.7 0 3.22
p16 position 7 101 2.9 ± 2.2 1.06 16.73
p53 position 1 91 2.8 ± 1.7 1.40 15.59
p53 position 2 91 8.3 ± 2.7 3.91 18.84
p53 position 3 91 2.8 ± 1.0 1.57 7.03
p53 position 4 91 3.8 ± 1.5 0 8.6
Table 2. Distribution of water and urinary arsenic concentrations.
Percentile
 Minimum 10th 25th 50th 75th 90th Maximum
Drinking water As (μg/L) < 1 < 1 < 1 1.2 3.7 61 230
Total urinary As (μg/L) 0.05 2.67 5.95 12.35 29.54 60.30 260.29
Total urinary As (μg As/g creatinine) 0.004 0.18 0.3 0.48 0.80 1.42 21.87
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(adjusted β = 1.36, SE = 0.42, p = 0.002) com-
pared with the lowest tertile of TUA/g.
In maternal leukocytes (Figure 1B), 
LINE-1 methylation was not significantly asso-
ciated with drinking-water As (Table 3). But 
LINE-1 methylation in maternal leukocytes 
was 1.08% higher among those in the highest 
tertile of TUA/g (adjusted β = 1.08, SE = 0.51, 
p = 0.04) compared with the lowest tertile.
No significant associations were observed 
between Alu methylation in umbilical cord 
leukocytes and drinking-water As (Table 3). 
Nor was there any association between umbil-
ical cord Alu methylation and TUA/g. Nor 
were any significant associations observed 
between Alu methylation in maternal leuko-
cytes and drinking-water As or when exposure 
was expressed as TUA/g.
p16 and p53. Associations between mater-
nal As exposure and methylation of CpG sites 
within the promoter regions of p16 and p53 
in umbilical cord leukocytes are presented in 
Table 4. When As exposure was categorized 
by drinking-water As, methylation at positions 
2, 5, 6, and 7 within the promoter region of 
p16 increased in the highest versus lowest ter-
tile of As exposure. For example, methylation 
at position 2 increased 0.52% in associa-
tion with the highest versus lowest tertile of 
drinking water after adjustment for maternal 
BMI and prematurity (β = 0.52, SE = 0.26, 
p = 0.05). Methylation at position 2 was also 
increased among those in the highest versus 
lowest tertile of creatinine-adjusted urinary As 
(β = 0.54, SE = 0.30, p = 0.07).
The association between As exposure 
and methylation in p16 and p53 in maternal 
blood are presented in Table 5. In maternal 
blood, methylation at CpG positions 1, 2, 3, 
and 6 in p16 was associated with creatinine-
 adjusted urinary As, although except for 
position 3, associations were stronger for 
the medium versus highest tertile of TUA/g. 
Methylation of the CpG site at position 3 was 
also increased for highest versus lowest tertile 
of drinking-water As (β = 0.28, SE= 0.14, p = 
0.05 for the highest tertile of drinking-water 
As, and β = 0.34, SE = 0.15, p = 0.03 for the 
highest tertile of TUA/g.).
No significant associations were observed 
between As exposure and methylation at 
any of the 4 CpG sites measured in p53 in 
either umbilical cord or maternal leukocytes 
(Tables 4 and 5).
Discussion
In our study population, As exposure mea-
sured before the 25th week of gestational age 
was associated with modest increases in CpG 
methylation in LINE-1 repeated elements 
measured in DNA extracted from leukocytes of 
healthy pregnant women and their newborns. 
Methylation at some of the CpG sites within 
the promoter region of p16 also increased with 
As exposure, although the strongest associa-
tions were in the middle tertiles in all but one 
position, which could indicate a nonlinear 
dose–response relationship. This leads to spec-
ulation that moderate levels of arsenic exposure 
may increase methylation within the promoter 
region of p16 in pregnant women and their 
infants although additional experimental and 
epidemiological studies are needed to validate 
these findings.
Although this is the first epidemiologi-
cal study to observe an association between 
moderate As exposure and DNA methylation 
in newborns, previous experimental studies 
have shown that high levels of As can alter 
DNA methylation. Cell culture experiments in 
human lung, kidney, and keratinocytes show 
that As increases methylation within the pro-
moter regions of the tumor suppressor gene 
p53, the non canonical WNT signaling path-
way and the death-associated protein kinase 
(DAPK) gene, but reduces global DNA methy-
lation (Chen et al. 2004; Chen et al. 2007; 
Christensen et al. 2007; Huang et al. 2011; 
Jensen et al. 2008, 2009; Mass and Wang 
1997; Xie et al. 2007; Zhao et al. 1997; Zhong 
and Mass 2001). In mice, chronic exposure 
to As induced global DNA hypomethylation, 
estrogen-receptor α (ERα) hypomethylation, 
and up-regulation of ERα expression (Chen 
et al. 2004).
Epidemiological studies in adults have also 
observed associations between As and DNA 
methylation. In a bladder cancer study con-
ducted in New Hampshire (USA), tumor 
Table 3. Estimates and 95% confidence intervals (CIs) from general linear regression models that compared DNA methylation (%mC) in leukocytes according to 
tertiles of drinking-water As (μg/L) and TUA/g (μg/g). 
Drinking-water As TUA/g
Crude Adjusted Crude Adjusted
β (95% CI) p-Value β (95% CI) p-Value β (95% CI) p-Value β (95% CI) p-Value
Cord blood
LINE-1 High 0.79 (–0.01, 1.60) 0.05 0.75 (–0.02, 1.53) 0.06 1.56 (0.70, 2.41) 0.001 1.36 (0.52, 2.21) 0.002
Med 1.15 (0.19, 2.11) 0.02 1.10 (0.17, 2.04) 0.02 0.37 (–0.46, 1.20) 0.38 0.33 (–0.48, 1.14) 0.43
Low Ref  Ref  Ref Ref
Alu High –0.26 (–0.57, 0.06) 0.11 –0.25 (–0.57, 0.07) 0.13 –0.01 (–0.35, 0.34) 0.97 –0.02 (–0.38, 0.34) 0.91
Med –0.19 (–0.57, 0.19) 0.33 –0.16 (–0.55, 0.23) 0.43 –0.15 (–0.50, 0.20) 0.39 –0.17 (–0.51, 0.18) 0.35
Low Ref Ref Ref Ref
Maternal blood
LINE-1 High 0.66 (–0.27, 1.59) 0.16 0.63 (–0.29, 1.55) 0.18 1.13 (0.11, 2.15) 0.03 1.08 (0.07, 2.10) 0.04
Med 0.62 (–0.54, 1.78) 0.29 0.53 (–0.62, 1.69) 0.36 0.12 (–0.88, 1.12) 0.81 0.13 (–0.87, 1.12) 0.80
Low Ref Ref Ref Ref
Alu High –0.19 (–0.51, 0.13) 0.24 –0.21 (–0.53, 0.11) 0.20 –0.07 (–0.42, 0.29) 0.71 –0.09 (–0.44, 0.27) 0.63
Med –0.16 (–0.56, 0.25) 0.44 –0.18 (–0.59, 0.22) 0.38 0.27 (–0.08, 0.62) 0.12 0.28 (–0.07, 0.62) 0.12
Low Ref Ref Ref  Ref
Abbreviations: Med, medium; Ref, reference. Models are adjusted for maternal BMI (continuous). Additionally, cord blood models are adjusted for prematurity (< 37 or ≥ 37 weeks  gestation).
Figure 1. The average %mC in LINE-1 repeated elements was estimated from general linear regres-
sion models for each tertile of As exposure measured in drinking-water As and TUA/g for (A) umbilical 
cord leukocytes adjusted for average maternal BMI (21.0) and prematurity (≥ 37 weeks gestation) and 
(B) maternal leukocytes adjusted for average maternal BMI (21.0). p-Values evaluate the difference in 
LINE-1 methylation levels at each tertile of As exposure compared to the lowest tertile (Ref, reference). 
Error bars represent SEs.
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suppressor genes RASSF1A and PRSS3 were 
hypermethylated in bladder cancer tumors col-
lected from 18 individuals who had toenail As 
levels at or above the 95th percentile compared 
with 318 tumors from individuals with toenail 
arsenic levels below the 95th percentile (Marsit 
et al. 2006). In adults participating in a 12-week 
folic acid supplementation trial (n = 294) in 
Bangladesh, global DNA methylation in leu-
kocytes increased with urinary arsenic levels 
among 104 folate replete adults (Pilsner et al. 
2007). In a skin cancer study in West Bengal, 
India, 72 adults who were exposed to As and 
had dermal symptoms of chronic As toxicity 
had higher DNA methylation of the promoter 
regions of p53 and p16 than 24 unexposed 
individuals (Chanda et al. 2006). Additionally, 
DNA methylation in leukocytes appeared to 
have a nonlinear exposure–response relation-
ship, such that global methylation increased 
when drinking water As concentrations were 
250–500 μg/L but then decreased when As 
was > 500 μg/L (Majumdar et al. 2010). In 
Guizhou, China, a case–control study reported 
that methylation of the promoter region of p16 
was increased in 103 adult arsenicosis patients 
compared with 110 controls, and that p16 
hypermethylation increased with the sever-
ity of the arsenic-related skin lesion (Zhang 
et al. 2007). Furthermore, a small case–con-
trol study performed a genome-wide screen of 
DNA methylation patterns and identified 182 
hypermethylated genes in peripheral lympho-
cyte DNA in 8 adults with arsenic-related skin 
lesions compared with 8 adults without arsenic-
related skin lesions (Smeester et al. 2011).
Although it is not known whether the 
small differences in leukocyte methylation in 
LINE-1 or p16 observed in this study are asso-
ciated with any adverse health effects, transcrip-
tional silencing through hyper methylation of 
tumor-suppressor gene promoters and chro-
mosomal instability from aberrant methyla-
tion of repeated elements are consistent with 
the epigenetic events observed in carcinogen-
esis (Feinberg and Tycko 2004; Ogino et al. 
2008). Furthermore, inactivation of p16, by 
methylation, which is frequently detected in 
tumor tissues, has led to speculation that loss of 
cell cycle control resulting from methylation of 
p16 may be an early biomarker of carcinogen-
esis (Attri et al. 2005; Gazzeri et al. 1998).
An important consideration for this study is 
that blood contains a mixture of different white 
blood cell types and umbilical cord blood can 
contain stem cells. Arsenic affects erythropoiesis 
(Saulle et al. 2006) and may affect white blood 
cell populations (Parmar and Tallman 2003). 
Because we analyzed DNA from whole blood 
we are capturing a mixture of leukocytes, and 
the different responses we observed between 
mothers and their infants may be attributable 
to differing white blood cell subpopulations or 
stem cells. Other limitations of this study are 
its small sample size; the skewed distribution 
of As exposures, which makes it difficult to dis-
cern substantial differences between the low and 
medium tertiles of As exposure; and As expo-
sure measurements at only one point in time 
during early pregnancy. Also, we could adjust 
for the dilution of urine using only creatinine 
because we did not measure the specific gravity 
Table 4. Estimates and 95% confidence intervals (CIs) from general linear 
regression models that compared DNA methylation (%mC) in umbilical cord 
leukocytes according to tertiles of drinking-water As and TUA/g. 
Drinking-water As (%mC) TUA/g (%mC)
Site As tertile β (95% CI) p-Value β (95% CI) p-Value
p16
pos1 High –0.06 (–0.64, 0.53) 0.85 0.07 (–0.58, 0.73) 0.83
 Med 0.36 (–0.36, 1.08) 0.33 0.01 (–0.62, 0.65) 0.96
 Low Ref Ref
pos2 High 0.52 (0.004, 1.04) 0.05 0.54 (–0.05, 1.12) 0.07
 Med 0.78 (0.15, 1.42) 0.02 0.16 (–0.42, 0.73) 0.59
 Low Ref Ref
pos3 High 0.02 (–0.29, 0.34) 0.88 –0.01 (–0.36, 0.34) 0.98
 Med 0.11 (–0.28, 0.50) 0.58 –0.20 (–0.54, 0.14) 0.25
 Low Ref  Ref
pos4 High 0.31 (–0.08, 0.70) 0.12 0.21 (–0.23, 0.65) 0.35
 Med 0.33 (–0.15, 0.81) 0.17 –0.06 (–0.49, 0.37) 0.79
 Low Ref  Ref  
pos5 High 0.50 (0.14, 0.86) 0.01 0.17 (–0.24, 0.58) 0.41
 Med 0.17 (–0.27, 0.61) 0.45 –0.15 (–0.54, 0.25) 0.46
 Low Ref  Ref
pos6 High 0.37 (0.68, 0.57) 0.02 0.15 (–0.20, 0.50) 0.40
 Med 0.18 (–0.20, 0.57) 0.34 0.16 (–0.19, 0.50) 0.37
 Low Ref Ref
pos7 High 0.52 (0.07, 0.96) 0.02 0.33 (–0.18, 0.83) 0.20
 Med 0.39 (–0.16, 0.94) 0.16 –0.07 (–0.56, 0.42) 0.77
 Low Ref Ref
p53
pos1 High 0.22 (–0.18, 0.63) 0.27 0.30 (–0.18, 0.74) 0.19
 Med –0.18 (–0.65, 0.30) 0.46 0.20 (–0.23, 0.64) 0.36
 Low Ref Ref
pos2 High –0.93 (–2.15, 0.30) 0.14 –0.27 (–1.64, 1.10) 0.70
 Med –1.17 (–2.62, 0.28) 0.11 –0.35 (–1.69, 0.99) 0.61
 Low Ref Ref
pos3 High 0.04 (–0.69, 0.48) 0.81 0.21 (–0.43, 0.85) 0.51
 Med 0.00 (–0.92, 0.46) 1.00 0.27 (–0.36, 0.89) 0.40
 Low Ref Ref  
pos4 High –0.10 (–0.78, 0.59) 0.78 –0.21 (–0.97, 0.54) 0.57
 Med 0.00 (–0.82, 0.81) 0.99 –0.12 (–0.86, 0.62) 0.75
 Low Ref Ref
Abbreviations: Med, medium; pos, position; Ref, reference.
Models adjusted for maternal BMI (continuous) and prematurity (< 37 or ≥ 37 weeks ges-
tation). Low tertile (≤ 1 μg/L); medium tertile (1–1.9 μg/L); high tertile (> 1.9 μg/L).
Table 5. Estimates and 95% confidence intervals (CIs) from general linear 
regression models that compared DNA methylation (%mC) in maternal leuko-
cytes according to tertiles of drinking-water As and TUA/g.
As tertile
Drinking-water As (%mC) TUA/g (%mC)
Site β (95% CI) p-Value β (95% CI) p-Value
p16
pos1 High –0.01 (–0.70, 0.68) 0.97 0.46 (–0.27, 1.20) 0.21
 Med –0.28 (–1.13, 0.58) 0.53 1.00 (0.28, 1.73) 0.01
 Low Ref Ref
pos2 High 0.27 (–0.48, 1.02) 0.47 0.73 (–0.07, 1.53) 0.07
 Med –0.08 (–1.01, 0.85) 0.86 1.13 (0.35, 1.92) 0.01
 Low Ref Ref
pos3 High 0.28 (0, 0.57) 0.05 0.34 (0.03, 0.65) 0.03
 Med 0.07 (–0.28, 0.42) 0.69 0.27 (–0.04, 0.57) 0.08
 Low Ref Ref
pos4 High 0.13 (–0.32, 0.59) 0.56 0.30 (–0.16, 0.83) 0.24
 Med –0.10 (–0.67, 0.46) 0.72 0.38 (–0.08, 0.89) 0.14
 Low Ref  Ref
pos5 High 0.06 (–0.26, 0.38) 0.70 0.10 (–0.25, 0.45) 0.58
 Med –0.22 (–0.62, 0.17) 0.27 0.29 (–0.05, 0.64) 0.10
 Low Ref Ref
pos6 High 0.19 (–0.10, 0.49) 0.20 0.29 (–0.03, 0.61) 0.07
 Med –0.01 (–0.38, 0.36) 0.96 0.38 (0.06, 0.69) 0.02
 Low Ref Ref
pos7 High 0.53 (–0.40, 1.47) 0.26 0.48 (–0.56, 1.52) 0.36
 Med –0.40 (–1.57, 0.77) 0.50 0.78 (–0.25, 1.80) 0.13
 Low Ref Ref
p53
pos1 High –0.23 (–1.03, 0.57) 0.57 –0.21 (–1.11, 0.69) 0.64
 Med –0.19 (–1.21, 0.84) 0.72 –0.61 (–1.50, 0.29) 0.18
 Low Ref Ref
pos2 High –0.29 (–1.52, 0.94) 0.64 –0.61 (–2.00, 0.77) 0.38
 Med –0.15 (–1.72, 1.42) 0.85 –0.59 (–1.97, 0.79) 0.40
 Low Ref Ref
pos3 High 0.08 (–0.38, 0.54) 0.73 –0.04 (–0.56, 0.47) 0.87
 Med –0.20 (–0.79, 0.38) 0.49 –0.30 (–0.81, 0.22) 0.25
 Low Ref  Ref
pos4 High 0.48 (0.34) 0.16 0.31 (0.39) 0.43
 Med –0.01 (0.44) 0.97 –0.24 (0.39) 0.54
 Low Ref Ref
Abbreviations: Med, medium; pos, position; Ref, reference. Models adjusted for 
 maternal BMI. Low tertile (≤ 0.35 μg/g); medium tertile (0.35 – 0.66 μg/g); high tertile 
(> 0.66 μg/g).
Kile et al.
1066 volume 120 | number 7 | July 2012 • Environmental Health Perspectives
of urine. This is problematic because creatinine, 
arsenic metabolism, and DNA methylation are 
all mediated by one-carbon metabolism (Pilsner 
et al. 2009). Subsequently, adjusting total uri-
nary arsenic for creatinine, instead of specific 
gravity, could be a source of bias in this study.
However, previous research has shown 
that arsenic can alter DNA methylation, and 
it is biologically plausible that early pregnancy 
may be a critical window for exposure to epi-
genetic toxicants because methylation marks 
are being established in the fetus. Additionally, 
we used both environmental and personal 
measurements to characterize As exposure. All 
methylation assays were run in a single batch 
to reduce analytical variability, and technicians 
were blinded to exposure. Finally, pyrosequenc-
ing is a sensitive method that quantifies very 
small changes in DNA methylation at specific 
loci and sequences in the genome. Other com-
monly used DNA methylation assays might not 
have been able to detect these small changes.
In conclusion, this study showed an asso-
ciation between moderate drinking-water As 
exposure and increased DNA methylation in 
LINE-1, and to a lesser extent increased methy-
lation within the promoter region of p16, in 
leukocytes in healthy pregnant women and their 
infants. Additional research on low-level arsenic 
exposure is needed to confirm these findings and 
determine whether these small changes in DNA 
methylation are associated with any adverse 
health effects. It is also critically important that 
efforts continue to reduce As exposure from 
contaminated drinking water in Bangladesh. 
correction
The Supplemental Material was omitted 
from the manuscript originally published 
online. It has been added online, and the 
text citations to it have been added here.
RefeRences
Alam MGM, Allinson G, Stagnitti F, Tanaka A, Westbrooke M. 
2002. Arsenic contamination in Bangladesh groundwater: 
a major environmental and social disaster. Int J Environ 
Health Res 12(3):236–253.
Amini M, Abbaspour KC, Berg M, Winkel L, Hug SJ, Heohn E, 
et al. 2008. Statistical modeling of global geogenic  arsenic 
contamination in groundwater. Enviro Sci Technol 
42(10):3669–3675.
Attri J, Srinivasan R, Majumdar S, Radotra BD, Wig J. 2005. 
Alterations of tumor suppressor gene p16INK4a in pancre-
atic ductal carcinoma. BMC Gastroenterol 22:1–10.
Barker DJP. 1992. Fetal and infant origins of disease. BMJ 
Books, London.
Bates MN, Smith AH, Hopenhayn-Rich, C. 1992. Arsenic inges-
tion and internal cancers: a review. Am J Epidemiol 
135(5):462-476.
British Geological Survey. 2001.Arsenic Contamination of 
Groundwater in Bangladesh (Kinniburgh DG, Smedley PL, 
eds). British Geological Survey Technical Report WC/00/19. 
Keyworth, UK:British Geological Survey.
Chanda S, Dasgupta UB, Guhamazumder D, Gupta M, 
Chaudhuri U, Lahiri S, et al. 2006. DNA hypermethylation of 
promoter of gene p53 and p16 in arsenic-exposed people 
with and without malignancy. Toxicol Sci 89(2):431–437.
Chen H, Li S, Liu J, Diwan BA, Barrett JC, Waalkes MP. 2004. 
Chronic inorganic arsenic exposure induces hepatic global 
and individual gene hypomethylation: implications for arse-
nic hepatocarcinogenesis. Carcinogenesis 25:1779–1786.
Chen WT, Hung WC, Kang WY, Huang YC, Chai CY. 2007. Urothelial 
carcinomas arising in arsenic-contaminated areas are asso-
ciated with hypermethylation of the gene promoter of the 
death-associated kinase. Histopathology 51(6):785–792.
Christensen BC, Marsit CJ, Welsh MM, Nelson HH, Kelsey KT. 
2007. Genome-wide alterations in CpG island methylation 
induced by arsenite. Eur J Oncol 12(1):9–14.
Dolinoy DC, Huang D, Jirtle RL. 2007. Maternal nutrient supple-
mentation counteracts bisphenol A-induced DNA hypo-
methylation in early development. Proc Natl Acad Sci USA 
104(32):13056–13061.
Dolinoy DC, Weidman JR, Waterland RA, Jirtle RL. 2006. 
Maternal genistein alters coat color and protects A(vy) 
mouse offspring from obesity by modifying the fetal epig-
enome. Environ Health Perspect 114:567–572.
Edwards TM, Myers JP. 2007. Environmental exposures 
and gene regulation in disease etiology. Environ Health 
Perspect 115:1264–1270.
Feinberg AP, Tycko B. 2004. The history of cancer epigenetics. 
Nat Rev Cancer 4(2):143–153.
Gazzeri S, Gouyer V, Vour’ch C, Brambilla C, Brambilla E. 1998. 
Mechanisms of p16INK4A inactivation in nonsmall-cell 
lung cancers. Oncogene 16:497–504.
Geiman TM, Muegge K. 2010. DNA methylation in early 
develop ment. Mol Reprod Dev 77(2):105–113.
Hsueh YM, Huang YL, Huang CC, Wu WL, Chen HM, Yang MH, 
et al. 1998. Urinary levels of inorganic and organic arsenic 
metabolites among residents in an arseniasis-hyperendemic 
area in Taiwan J Toxicol Environ Health A 54(6):431–444.
Huang YC, Hung WC, Chen WT, Yu HS, Chai CY. 2011. Effects 
of DNMT and MEK inhibitors on the expression of RECK, 
MMP–9,–2, uPA and VEGF in response to arsenite stimula-
tion in human uroepithelial cells. Toxicol Lett 201(1):62–71.
Jensen TJ, Novak P, Eblin KE, Gandolfi AJ, Futscher BW. 2008. 
Epigenetic remodeling during arsenical-induced malignant 
transformation. Carcinogenesis 29(8):1500–1508.
Jensen TJ, Wozniak RJ, Eblin KE, Wnek SM, Gandolfi AJ, 
Futscher BW. 2009. Epigenetic mediated transcriptional acti-
vation of WNT5A participates in arsenical-associated malig-
nant transformation. Toxicol Appl Pharmacol 235(1):39–46.
Jirtle RL, Skinner MK. 2007. Environmental epigenomics and 
disease susceptibility. Nat Rev Genet 8(4):253–262.
Kaminen-Ahola NA, Ahola A, Maga M, Mallitt KA, Fahey P, 
Cox TC, et al. 2010. Maternal ethanol consumption alters 
the epigenotype and the phenotype of offspring in a mouse 
model. Plos Genet 6(1); doi:10.1371/journal.pgen.1000811 
[Online 15 January 2010].
Kile ML, Baccarelli A, Tarantini L, Hoffman E, Wright RO, 
Christiani DC. 2010. Correlation of global and gene- specific 
DNA methylation in maternal-infant pairs. PLoS ONE 
5(10):e13730; doi:10.1371/journal.pone.0013730 [Online 
29 October 2010].
Kochanek S, Renz D, Doerfler W. 1993. DNA methylation in the 
Alu sequences of diploid and haploid primary human cells. 
Embo J 12(3):1141–1151.
Majumdar S, Chanda S, Ganguli B, Mazumder DN, Lahiri S, 
Dasqupta UB. 2010. Arsenic exposure induces genomic 
hypermethylation. Environ Toxicol 25(3):315–318.
Mandal BK, Suzuki KT. 2002. Arsenic round the world: a review. 
Talanta 58(1):201–235.
Marsit CJ, Karagas MR, Danaee H, Liu M, Andrew A, Schned A, 
et al. 2006. Carcinogen exposure and gene promoter hyper-
methylation in bladder cancer. Carcinogenesis 27(1):112–116.
Mass MJ, Wang L. 1997. Arsenic alters cytosine methylation 
patterns of the promoter of the tumor suppressor gene p53 
in human lung cells: a model for a mechanism of carcino-
genesis. Mutat Res 386(3):263–277.
National Research Council. 2001. Arsenic in Drinking Water, 
2001 Update. Washington, DC:National Academy Press.
Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, 
Kirkner GJ, et al. 2008. LINE-1 hypomethylation is inversely 
associated with microsatellite instability and CpG island 
methylator phenotype in colorectal cancer. Int J Cancer 
122(12):2767–2773.
Parmar S, Tallman MS. 2003. Acute promyelocytic leukaemia: a 
review. Expert Opin Pharmacother 4(8):1379–1392.
Pavanello S, Bollati V, Pesatori AC, Kapka L, Bolognesi C, 
Bertazzi PA, et al. 2009. Global and gene-specific promoter 
methylation changes are related to anti-B[a]PDE-DNA 
adduct levels and influence micronuclei levels in poly-
cyclic aromatic hydrocarbon-exposed individuals. Int J 
Cancer 125(7):1692–1697.
Pilsner JR, Liu X, Ahsan H, Ilievski V, Slavkovich V, Levy D, 
et al. 2007. Genomic methylation of peripheral blood leuko-
cyte DNA: influences of arsenic and folate in Bangladeshi 
adults. Am J Clin Nutr 86(4):1179–1186.
Pilsner JR, Liu XH, Ahsan H, Ilievski V, Slavokovich V, Levy D, 
et al. 2009. Folate deficiency, hyperhomocysteinemia, low 
urinary creatinine, and hypomethylation of leukocycte 
DNA are risk factors for arsenic-induced skin lesions. 
Environ Health Perspect 117:254–260.
Rangwala SH, Zhang L, Kazazian HH. 2009. Many LINE1 ele-
ments contribute to the transcriptome of human somatic 
cells. Genome Biol 10(9):R100; doi:10.1186/gb-2009-10-9-
r100 [Online 22 September 2009].
Sasaki H, Matsui Y. 2008. Epigenetic events in mammalian 
germ-cell development: reprogramming and beyond. Nat 
Rev Genet 9(2):129–140.
Saulle E, Riccioni R, Pelosi E, Stafness M, Mariani G, De Tuglie G, 
et al. 2006. In vitro dual effect of arsenic trioxide on 
hemopoiesis: inhibition of erythropoiesis and stimulation 
of megakaryocytic maturation. Blood Cells Mol and Dis 
36(1):59–76.
Smeester L, Rager JE, Bailey KA, Guan XJ, Smith N, Garcia-
Vargas G, et al. 2011. Epigenetic changes in individuals 
with arsenicosis. Chem Res Toxicol 24(2):165–167.
Sohel N, Persson LA, Rahman M, Streatfield PK,Yunus M, 
Ekstrom EC, et al. 2009. Arsenic in drinking water and 
adult mortality: a population-based cohort study in rural 
Bangladesh. Epidemiology 20(6):824–830.
Tokar EJ, Diwan BA, Ward JM, Delker DA, Waalkes MP. 2011a. 
Carcinogenic effects of “whole-life” exposure to inorganic 
arsenic in CD1 mice. Toxicol Sci 119(1):73–83.
Tokar EJ, Qu W, Waalkes MP. 2011b. Arsenic, stem cells, 
and the developmental basis of adult cancer. Toxicol Sci 
120:S192–S203.
Vahter M. 2008. Health effects of early life exposure to arsenic. 
Basic Clin Pharmacol Toxicol 102(2):204–211.
Waalkes MP, Ward JM, Diwan BA. 2004. Induction of tumors of 
the liver, lung, ovary and adrenal in adult mice after brief 
maternal gestational exposure to inorganic arsenic: promo-
tional effects of postnatal phorbol ester exposure on hepatic 
and pulmonary, but not dermal cancers. Carcinogenesis 
25(1):133–141.
Waalkes MP, Ward JM, Liu J, Diwan BA. 2003. Transplacental 
carcinogenicity of inorganic arsenic in the drinking water: 
induction of hepatic, ovarian, pulmonary, and adrenal 
tumors in mice. Toxicol Appl Pharmacol 186(1):7–17.
Waterland RA, Jirtle RL. 2003. Transposable elements: targets 
for early nutritional effects on epigenetic gene regulation. 
Mol Cell Biol 23(15):5293–5300.
Waterland RA, Michels KB. 2007. Epigenetic epidemiology 
of the developmental origins hypothesis. Annu Rev Nutr 
27:363–388.
Wu GY, Bazer FW, Cudd TA, Meininger CJ, Spencer TE. 
2004. Maternal nutrition and fetal development. J Nutr 
134(9):2169–2172.
Xie Y, Liu J, Benbrahim-Tallaa L, Ward JM, Logsdon D, 
Diwan BA, et al. 2007. Aberrant DNA methylation and gene 
expression in livers of newborn mice transplacentally 
exposed to a hepatocarcinogenic dose of inorganic arse-
nic. Toxicology 236(1–2):7–15.
Zhang AH, Bin HH, Pan XL, Xi XG. 2007. Analysis of p16 gene 
mutation, deletion and methylation in patients with arse-
niasis produced by indoor unventilated-stove coal usage 
in Guizhou, China. J Toxicol Environ Health A 70(11–
12):970–975.
Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. 1997. 
Association of arsenic-induced malignant transformation 
with DNA hypomethylation and aberrant gene expression. 
Proc Natl Acad Sci USA 94:10907–10912.
Zhong CX, Mass MJ. 2001. Both hypomethylation and hyper-
methylation of DNA associated with arsenite exposure in 
cultures of human cells identified by methylation-sensitive 
arbitrarily-primed PCR. Toxicol Lett 122(3):223–234.
